ConductScience.org, home

Paper19680293

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.

Gazdar AF. Oncogene, 2009. Cited by 797 papers, by iCite.

Cite this record

ConductScience Library. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Papers, record 19680293. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19680293

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
PubMed
Journal
Oncogene
PubMed
Year
2009
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
797
iCite
Relative citation ratio, by iCite
17.6
iCite
Revised in PubMed
2025-05-29
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gazdar AFA F

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Drug Resistance, NeoplasmMajor topic
ErbB ReceptorsMajor topic
Lung NeoplasmsMajor topic
Point MutationMajor topic
Protein Kinase InhibitorsMajor topic
Erlotinib Hydrochloride
Gefitinib
Gene Amplification
Humans
Protein Structure, Tertiary
Proto-Oncogene Proteins
Proto-Oncogene Proteins c-met
Proto-Oncogene Proteins p21(ras)
Quinazolines
Receptors, Growth Factor
Sequence Deletion
Treatment Outcome
ras Proteins

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P50 CA070907NCI NIH HHSUnited StatesP50CA070907PubMed and NIH
P50CA70907NCI NIH HHSUnited StatesP50CA070907PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
114570950Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.JAMA2003https://conductscience.org/library/papers/14570950PubMed
216187797Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.PLoS Med2005https://conductscience.org/library/papers/16187797PubMed
316777603An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.Cell2006https://conductscience.org/library/papers/16777603PubMed
419276259Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.Clin Cancer Res2009https://conductscience.org/library/papers/19276259PubMed
517671147HKI-272 in non small cell lung cancer.Clin Cancer Res2007https://conductscience.org/library/papers/17671147PubMed
615738541Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.J Clin Oncol2005https://conductscience.org/library/papers/15738541PubMed
715851406Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.Ann Oncol2005https://conductscience.org/library/papers/15851406PubMed
818375904Structure and clinical relevance of the epidermal growth factor receptor in human cancer.J Clin Oncol2008https://conductscience.org/library/papers/18375904PubMed
915604253Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.Cancer Res2004https://conductscience.org/library/papers/15604253PubMed
1018355544Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer.Ann Thorac Surg2008https://conductscience.org/library/papers/18355544PubMed
1116705038Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.Genes Dev2006https://conductscience.org/library/papers/16705038PubMed
1216014882Erlotinib in previously treated non-small-cell lung cancer.N Engl J Med2005https://conductscience.org/library/papers/16014882PubMed
1318227510The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.Proc Natl Acad Sci U S A2008https://conductscience.org/library/papers/18227510PubMed
1415710947Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.J Clin Oncol2005https://conductscience.org/library/papers/15710947PubMed
1516467097Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.Clin Cancer Res2006https://conductscience.org/library/papers/16467097PubMed
1616912195Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.Cancer Res2006https://conductscience.org/library/papers/16912195PubMed
1716818686Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.Clin Cancer Res2006https://conductscience.org/library/papers/16818686PubMed
1816204070Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.Cancer Res2005https://conductscience.org/library/papers/16204070PubMed
1916043828
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
J Clin Oncol2005https://conductscience.org/library/papers/16043828PubMed
2018509184Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.J Clin Oncol2008https://conductscience.org/library/papers/18509184PubMed

See all 49 referencesDownload CSV of references

Cited by495

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 797 citations.

PMIDTitleJournalYearIn PapersSource
42959345Disease-guided targeted protein degradation and clearance: matching strategies to pathological protein states.Front Med (Lausanne)2026https://conductscience.org/library/papers/42959345PubMed
42794834Time-Resolved Network Entropy Analysis Identifies a CTNND1-VAV3 Subnetwork in Gefitinib-Resistant NSCLC.Int J Mol Sci2026https://conductscience.org/library/papers/42794834PubMed
42723470Discovery of Potent EGFR Inhibitors for Del19 and L858R/T790M Mutants Through Structure-Based Virtual Screening and Biological Evaluation.Chem Biol Drug Des2026https://conductscience.org/library/papers/42723470PubMed
42653127From Descriptor Learning to Binding Stability: An Explainable Machine Learning Pipeline for EGFR Double-Mutant Inhibitor Discovery.Int J Mol Sci2026https://conductscience.org/library/papers/42653127PubMed
42361448Association of TP53 gain-of-function mutations with early osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma.ESMO Open2026https://conductscience.org/library/papers/42361448PubMed
42291370Patterns of central nervous system disease and molecular landscape in epidermal growth factor receptor exon 20 insertion mutated non-small cell carcinoma.Transl Lung Cancer Res2026https://conductscience.org/library/papers/42291370PubMed
42249090Integrative structural and dynamics studies of epidermal growth factor receptor (EGFR).Exp Mol Med2026https://conductscience.org/library/papers/42249090PubMed
42170254The resistance landscape of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer: molecular mechanisms and novel therapeutic strategies.Transl Lung Cancer Res2026https://conductscience.org/library/papers/42170254PubMed
42154197EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer: Current Treatment Landscape and Future Directions.Drugs2026https://conductscience.org/library/papers/42154197PubMed
42142369Gender Differences in EGFR-TKI-Related Adverse Events: A Pharmacovigilance Study Based on the FAERS Database.Cancer Control2026https://conductscience.org/library/papers/42142369PubMed
42101621The critical role of accurate neoplastic cell percentage (NCP) assessment: investigating targeted training strategies for pulmonary biopsy and cytology specimens.Virchows Arch2026https://conductscience.org/library/papers/42101621PubMed
42006277Mutation-Specific Response to Ramucirumab in EGFR-Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study).JTO Clin Res Rep2026https://conductscience.org/library/papers/42006277PubMed
41822315Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.World J Oncol2026https://conductscience.org/library/papers/41822315PubMed
41799114EGFR Mutations and Tyrosine Kinase Inhibitors: Structural Insights and Therapeutic Advances.ACS Omega2026https://conductscience.org/library/papers/41799114PubMed
41743381The relationship between genetic mutations and organ metastasis in non-small cell lung cancer.Ther Adv Med Oncol2026https://conductscience.org/library/papers/41743381PubMed
41710724Frequency of the L858R Mutation in Exon 21 of the Epidermal Growth Factor Receptor in Patients with Non-Small Cell Lung Cancer.Iran J Pathol2026https://conductscience.org/library/papers/41710724PubMed
41710084Metastatic breast cancer in primary lung cancer with compound EGFR mutations: A case report.Oncol Lett2026https://conductscience.org/library/papers/41710084PubMed
41670652Beyond the membrane: rethinking EGFR signaling in physiology and cancer.Cell Mol Life Sci2026https://conductscience.org/library/papers/41670652PubMed
41592227IsoPS-DIA: Dual Functionality of Absolute Targeted Quantification and Global Proteome Profiling.Anal Chem2026https://conductscience.org/library/papers/41592227PubMed
41590374Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option?Curr Oncol2026https://conductscience.org/library/papers/41590374PubMed

See all 495 cited byDownload CSV of cited by

Genes12

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19680293

GET https://conductscience.org/api/papers/v1/19680293/references?page=2